中文
About Us
Corporate Overview
Management Team
Board of Directors
Contact Us
Our Focus
Metabolic Diseases
Viral Diseases
Cancer
Exploratory Indications
Products&Pipeline
Pipeline
Products
Clinical Trials
Partnership
Investors
Financials & Filing
News
Careers
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Ascletis and Roche Enter Exclusive Pegasys Partnership in China for Viral Hepatitis
2018-11-20
Ascletis Appoints Dr. Lindi Tan as Chief Financial Officer
2018-11-12
Ascletis to Present Phase II / III Clinical Study for Its Innovative All-oral HCV Treatment at the 69th Annual meeting of AASLD
2018-11-06
Ascletis' Ravidasvir NDA Proposed for Priority Review by the CFDA
2018-10-18
Ascletis' Ganovo is Eligible for Shaoxing Government Funding Subsidy Program to Treat HCV Patients
2018-10-15
Ganovo® Enrolled in the Basic Medical Insurance of Tianjin--Capped Reimbursement-Per-Patient Pilot Program
2018-09-26
Ascletis Invited to attend the Summer Davos Forum Tianjin 2018
2018-09-17
Ascletis’ NDA for Its All-oral HCV Treatment Accepted by CFDA
2018-08-01
Ascletis Filed NDA for Its All-oral HCV Treatment
2018-07-31
Ganovo® Phase III Clinical Study Won the Top Award at the Infectious Disease National Congress of Chinese Medical Association
2018-07-30
1
2
»